This $4.3 billion acquisition is expected to be modestly accretive to Johnson & Johnson's bottom line.
The development-stage biotech may not have any earnings, but it's producing plenty of data to keep investors interested.
Earnings, insider buying, and criminal probes? Oh, my!
The biotech calendar is already chock-full of major catalysts in 2017. Here's a look at seven stocks that investors will definitely want to keep an eye on next year.
The company is reassuring investors that a new investigation into its billing practices isn't a big deal.
Looking for bargains in the sector best positioned to ride aging demographic trends? These five are screaming buys.
The smoke is beginning to clear, and one Wall Street investment bank likes what it sees.
Acadia's newly approved Parkison's disease drug could trigger a buyout. Here's why.
A collection of underperforming stocks held by Soros Fund Management that could be set to bounce strongly.
Offhand comments from Abbott's CEO, and a confusing statement from Alere makes a pending acquisition doubtful.